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ABSTRACT Pneumonia remains a worldwide health problem with a high rate of morbidity and mortality.
Identification of microbial pathogens which cause pneumonia is an important area for optimum clinical
management of pneumonia patients and is a big challenge for conventional microbiological methods. The
development and implementation of molecular diagnostic tests for pneumonia has been a major advance in
the microbiological diagnosis of respiratory pathogens in recent years. However, with new knowledge
regarding the microbiome, together with the recognition that the lungs are a dynamic microbiological
ecosystem, our current concept of pneumonia is not totally realistic as this new concept of pneumonia
involves a dysbiosis or alteration of the lung microbiome. A new challenge for microbiologists and
clinicians has therefore arisen. There is much to learn regarding the information provided by this new
diagnostic technology, which will lead to improvements in the time to antibiotic therapy, targeted antibiotic
selection and more effective de-escalation and improved stewardship for pneumonia patients. This article
provides an overview of current methods of laboratory diagnosis of pneumonia in the molecular age.
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Introduction
In 1930, pneumonia was the third most frequent cause of death in the USA [1]. Now, almost a century
later, and despite the introduction of antibiotics in the 1950s, pneumonia and other respiratory infections
remain the fourth most common cause of death worldwide [2]. Although the implementation of
vaccination programmes throughout the world has reduced the incidence of pneumonia, especially in
at-risk populations [3, 4], pneumonia still represents a major burden in terms of morbidity, mortality and
health costs, as well as days of work lost [5–8].
Microbiological diagnosis of pneumonia is fundamental to ensure appropriate antibiotic therapy, which is
associated with decreasing mortality [9]. However, aetiological diagnosis is only achieved in half of patients
and the initial antibiotic regimen should be chosen empirically in order to avoid the delay in instating
appropriate therapy that is associated with significant mortality [10, 11].
The Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) guidelines for
community-acquired pneumonia (CAP) recommend an optional microbiological diagnostic test in low-level
to mild cases of pneumonia, which should be selected as clinically indicated [12]. However, routine
microbiology should be performed in the case of pathogens that would significantly alter empirical decisions,
such as the influenza virus, Mycobacterium tuberculosis, Pseudomonas aeruginosa and especially
methicillin-resistant Staphylococcus aureus (MRSA), because the current guideline recommendation for severe
CAP is empirical therapy with β-lactam with macrolide or fluoroquinolone, which may not provide adequate
protection against MRSA [12]. Sputum cultures are only recommended for patients ill enough to require
intensive care unit (ICU) admission. This means that, depending on the epidemiology of microbial aetiology,
empirical treatments are chosen and given to patients as soon as possible after culture sample collection.
In current practice, most CAP patients can be treated following guidelines. The use of scores can help to
detect those patients with potential risk for multidrug-resistant pathogens or patients who require
non-standard treatment. [13–15] In these patients, molecular information, in addition to conventional
techniques, may be very useful. Current clinical practices have three main consequences. 1) The adequacy
of the initial antibiotic is the key factor for prognosis. It is known that mortality increases with each hour
of delay in initiating the correct therapy for pneumonia [16–19]. 2) Many patients receive broad-spectrum
antibiotic therapies until cultures are available and de-escalation cannot be performed quickly;
inappropriate use of antibiotics is thus more likely [20, 21]. 3) The emergence of antibiotic-resistant
pathogens related to selection pressure by over use of antibiotics worldwide [22, 23].
Antimicrobial resistance among Gram-positive cocci and Gram-negative bacilli is a major problem
worldwide [23–25]. The chapter in the State of the World’s Antibiotics report 2015 [26] on the human use
of antibiotics reports that consumption continues to increase (comparative data 2000–2010), and that
antibiotic treatment is inappropriate in between 20 and 50% of cases. The data on consumption per capita
by class and country reveal considerable variability between geographical locations, and this underlines
how much countries’ responses to the problem can vary [26]. Public campaigns encouraging the
implementation of specific measures have been successful [27, 28]. Most campaigns of this kind include
calls and warnings for better and more rapid diagnostic testing in order to reduce antibiotic administration
and to increase the use of microbe targeted therapies. The problem of microbial resistance is so serious
that, last year, President Obama drew attention to the threat it poses and called for greater research
funding [29]. However, the discovery of novel classes of antibiotics is more or less at a standstill, as the
costly and inefficient process is a challenge for pharmaceutical companies, who have abandoned their
investment in developing new antimicrobials. The Generating Antibiotic Incentives Now (GAIN) is a new
regulation of the Food and Drug Administration (FDA) aimed at providing economic incentives for
antibiotic drug discovery by offering market exclusivity and accelerated drug approval processes. The
regulation extends the exclusivity with which antibiotics that treat serious or life-threatening illnesses can
be sold without generic competition by 5 years. It also provides an additional 6 months of exclusivity to
the pharmaceutical or biotechnological company that identifies a companion diagnostic test. Additionally,
the FDA grants the option of accelerating the approval for the new antimicrobial [30].
Rapid molecular techniques (figure 1 and table 1) promise to be an effective tool to help guide appropriate
therapy and de-escalation from broad-spectrum antibiotic therapy. However, like any new medical
technology, they need to be validated in clinical practice.
In this article, we assess the most recent information on non-molecular and molecular methods for
detecting respiratory pathogens such as bacteria and viruses. The conclusions of this review are that for
most of the pathogens that cause pneumonia, there is the possibility of using rapid methods that may help
clinicians to use a better-targeted antibiotic and antiviral treatment. Point-of-care testing will be the best
way to implement these methods in clinical practice. However, before implementing these methods,
well-designed studies must be performed to determine their cost-effectiveness.
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Diagnosis of lower respiratory tract infections caused by conventional bacteria
Conventional microbiological diagnosis
In patients with CAP, microbiological investigation should consist of at least a sputum culture, a urinary
antigen test for Streptococcus pneumoniae and Legionella pneumophila, and a blood culture [12].
Additional serological investigation for atypical bacterial pathogens may be performed [12]. In studies
involving intensive microbiological investigation in patients with CAP, an aetiology was identified in 53–
75% of the sample [31–33]. The most common pathogens identified in these studies were S. pneumoniae,
Mycoplasma pneumoniae and Haemophilus influenzae.
Blood cultures performed before administration of antibiotic therapy have a very high specificity but are
positive in less than 20% of cases [12, 34]. Blood cultures from patients with severe CAP have a higher
yield because pathogens such as S. aureus and Gram-negative bacilli are frequently isolated and are not
affected by empirical therapy [12].
Pleural effusion is present in approximately 40% of CAP cases [35]. The specificity of pleural exudate
culture is very high, although the sensitivity is low because of the low incidence of invasion of the pleura
[35]. The sensitivity of the Gram stain is approximately 80% in cases of pneumococcal pneumonia [36]
and 78% for staphylococcal pneumonia, with a specificity of 93–96% [37].
Detection of S. pneumoniae using PCR
PCR is a molecular diagnostic technique based on DNA detection and offers the advantage of providing
results within a few hours. Furthermore, as PCR does not require viable bacteria, it is less influenced by
antimicrobial therapy. In a study by JOHANSSON et al. [38], in 184 consecutively admitted patients with
diagnosis of CAP, 80% of cases with a positive PCR test and negative sputum culture had been treated
with antibiotics prior to sputum sampling. In another study on the effect of antibiotic treatment on the
accuracy of diagnosing invasive pneumococcal disease using culture or molecular methods, an aetiological
diagnosis was established using molecular methods after 4 days or more of antibiotic treatment, and only
in the first 2 days of treatment using conventional diagnostic methods [39].
PCR-based detection of S. pneumoniae depends on the amplification of pneumococcus-specific genes.
Specific characteristics for this species are the production of toxins such as pneumolysin (Ply), as well as
the presence of surface antigens such as pneumococcal surface adhesin A (PsaA) and pneumococcal
autolysin A (LytA) [40]. However, studies investigating PCRs directed at the ply gene showed a lack of
sensitivity and specificity for pneumococcal disease [41]. It has also been shown that the ply gene was
present in some species of Streptococcal mouth flora such as Streptococcus mitis and Streptococcus oralis
[42]. To investigate whether gene targets other than the ply gene might be more specific, CARVALHO et al.
[42] compared two other targets: the lytA gene and the psaA gene. They showed that a PCR designed to
target the lytA gene was 100% specific, while that for the psaA gene was 98% specific. Another study
confirmed the high specificity for the lytA gene, in which no positive results were found in healthy control
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TABLE 1 Rapid microbiological tests for pneumonia diagnostics Q8
¶
.
Platform Pathogens Technology Sensibility/
specificity %
Clinical evidence Time/cost Sample
Curetis Unyvero system (P50
pneumonia) [122]
Bacterial/fungal pathogens
(18 types)
Antibiotic resistance
markers (22 types)
Multiplex-PCR (cartridge
system)
81/99 Potential for accurate and timely
detection of pathogens and their
resistance in severe pneumonia
4 h/€280–300 Sputum
BAL
BAS
Gene Xpert MRSA/SA [117, 118] MRSA
MSSA
Multiplex-PCR 99/72 Rapid, accurate tool for detecting
MRSA and MSSA in blood and
respiratory samples
1 h/€40 Blood
Nasal swabs
MALDI-TOF MS [108, 109, 110] Microorganisms (200 types) MS Identification directly
from bacterial/fungal
colonies
99–100/97–100 Rapid identification of
microorganisms in BAL was
associated with adjustment of
antibiotic therapy and a shorter
ICU stay for ventilated patients
with pneumonia
Detects certain types of antibiotic
resistance mechanisms
30 s–1 min/
€0.50–1.00
Colonies
Positive blood
cultures
Direct samples
(e.g. urine)
Gene Xpert Flu Assay [91] Influenza A/B (A/2009 H1) Multiplex-PCR 97–100/100 Rapid identification of
influenza virus in outbreaks
1 h/€40 Nasopharyngeal
swabs
Nasal aspirates
Nasal washes
Gene Xpert Flu/RSV Assay [91] Influenza A/B/RSV Multiplex-PCR 97–100/100 Rapid identification of influenza
virus in outbreaks
1 h/€40 Nasopharyngeal
swabs
Nasal aspirates
Nasal washes
eSensor Respiratory
Viral Panel [121]
Influenza A/B (seasonal H1,
H3, 2009 H1)
RSV A/B
Parainfluenza 1, 2, 3
Human metapneumovirus
Rhinovirus
Adenovirus B/E/C
Multiplex-PCR 98–99/99 Rapid identification of respiratory
viruses
Co-infection detection
8 h/no data Nasopharyngeal
swabs
FilmArray Respiratory
Panel [119, 120]
Adenovirus
Coronavirus 229E, OC43,
NL63, HKU1
Metapneumovirus
Influenza A, H3, H1, 2009 H1
Parainfluenza virus 1, 2, 3,
4, RSV
Rhinovirus/enterovirus
Bordetella pertussis
M. pneumoniae
C. pneumoniae
Nucleic acid purification,
reverse transcription,
high-order nested
multiplex-PCR and
DNA melting curve
analysis (unprocessed
biological/clinical
sample needed)
84–100/98–100 Detection of several respiratory
pathogens in one test
Significant impact on the care of
patients with respiratory
infections
1 h/€100–120 Nasopharyngeal
swabs
MALDI-TOF: matrix assisted laser desorption/ionisation time-of-flight; MS: mass spectrometry; MRSA: methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus; RSV:
respiratory syncytial virus; BAL: bronchoalveolar lavage; BAS ▪▪▪
Q9
¶
; ICU: intensive care unit
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subjects [43]. The diagnosis of pneumococcus using PCR tests can be applied to respiratory samples,
nasopharyngeal swabs and blood.
Sputum: PCR versus culture
Several studies have investigated the ability of PCR to detect S. pneumoniae in sputum [38, 44–46]. In two
Scandinavian studies, sputum was collected to perform PCR and culture. In the first study, 128 and 127
patients with CAP had at least one sputum sample analysed by culture and real-time PCR, respectively;
the PCR targeted the pneumolysin ( ply) gene of S. pneumoniae [38]. Sputum PCR was positive in 34
patients (27%) while sputum culture was positive in 19 patients (15%) (p<0.001). Sixteen of the 19
patients with a positive culture (84%) also had positive results with real-time PCR and 17 of the 34
patients with positive real-time PCR (50%) had negative cultures. Fourteen of these 17 patients (82%) had
been treated with antibiotics before sputum sampling. In the second study, a sputum culture was
performed in 112 patients and PCR in 103 patients: 36 patients (32%) had positive cultures and 55
patients (53%) had positive PCR results [47]. These studies suggest that sputum PCR is a more sensitive
method than sputum culture for detecting S. pneumoniae in patients hospitalised with CAP, especially in
those previously treated with antibiotics.
Blood/plasma: PCR versus culture
Blood cultures have a low sensitivity for detecting S. pneumoniae infections [31]; bacteraemia is found to
be present in about 20% of CAP cases where conventional blood cultures are used [34]. PCR may be able
to increase this sensitivity. One study, which assessed the role of PCR in whole blood when targeted at the
ply gene, showed a positive result in 22 of 40 patients (55%) with pneumococcal pneumonia, while blood
culture had a sensitivity of 28% (11 of 40 patients). The PCR was negative in all 30 patients with
non-pneumococcal pneumonia, giving a specificity of 100% [48]. Two studies in adult patients determined
the sensitivity of positive PCR results compared to positive blood cultures as a gold standard. In the first
study, 10 CAP patients had pneumococcal bacteraemia, PCR for lytA had a sensitivity of 70% (seven out
of 10) [49]. The second study showed a positive PCR lytA result for 10 out of 13 patients (77%) with S.
pneumoniae bacteraemia [50]. Furthermore, in a review assessing the value of PCR for diagnosing
pneumococcal bacteraemia, a sensitivity of 57.1% was reported (95% CI 45.7–67.8%). The PCR specificity
of 98.6% (95% CI 96.4–99.5%) was determined in a population of “patients with no disease”, defined as
healthy people or patients with bacteraemia caused by other bacteria [51].
Other PCR studies targeted at the lytA gene showed better performance with PCR than with blood culture.
In a prospective study including children younger than 15 years of age and adults with CAP, significantly
more cases of definite pneumococcal pneumonia were detected by PCR than by blood culture (27.1%
versus 5.0%; p<0.005). PCR in plasma was negative in a control group of 50 adults [43]. In another study,
including children aged 0–16 years, invasive pneumococcal disease was diagnosed in 47 of 292 patients
(16%). Of these patients, 45 (15.4%) tested positive with PCR and 11 (3.8%) tested positive with culture.
PCR was thus significantly more sensitive than culture in revealing bacteraemic pneumonia (OR 30.6, 95%
CI 5.8–97.5; p<0.001) [52]. The results of these two studies showed that molecular methods had higher
sensitivity than blood cultures in bacteraemic patients. One of the explanations may be that PCR can also
detect DNA from non-viable bacteria. In the latter case, the sensitivity of blood cultures may be influenced
by the fact that antibiotic treatment was started prior to culture collection. In one study, in patients with
CAP who received antibiotic treatment before hospital admission, PCR sensitivity was 7.0 times higher
than that of culture (p=0.043) [39].
Once a positive result is obtained from a PCR test in respiratory samples it is important to determine
whether this result reflects bacterial colonisation or infection. Recently, quantitative PCR assays have been
performed in different clinical samples (whole blood, sputum and nasopharyngeal specimens) that may
differentiate between colonisation and infection. In these studies, a cut-off of 104 to 105 colony forming
units per mL of pneumococcal DNA was described in non-HIV patients [49, 53, 54]. Furthermore, there is
some evidence that a quantitative approach can also be used to predict disease presentation and severity,
which may correlate with levels of pneumococci DNA in clinical PCR samples. In a prospective study of
353 patients with a diagnosis of CAP, RELLO et al. [55] showed that the median number of copies per mL
of S. pneumoniae DNA in whole blood samples was significantly higher in patients in whom septic shock
developed. In two other studies, a higher S. pneumoniae DNA load in blood samples was also associated
with the presence of more severe disease [50, 56]. Another beneficial application of PCR is that this
diagnostic method can be used for pneumococcal serotyping in cases of bacteraemia [52, 57]. This is
important for the identification of serotypes that may be responsible for severe CAP cases. These new tests
may also be useful for identifying the circulating pneumococcal serotypes in order to assess the effect of
pneumococcal vaccination.
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Additionally, PCR has the potential to recognise genes inducing antibiotic resistance [58]. At present,
however, conventional cultures remain the gold standard for determining resistance to antibiotics.
Diagnosis of viral and atypical pneumonia
Viral and atypical pathogens are common causes of pneumonia worldwide, representing 10–22% and 11–
28% of all CAP cases, respectively [59–63]. In a recent study by JAIN et al. [59] analysing 2320 cases of
pneumonia where an intensive microbiological diagnosis was applied, particularly viral molecular
techniques, microbial aetiology was identified in 853 (38%) cases. The three main causal agents found were
respiratory viruses (23%), bacterial aetiology (11%) and co-infections (3%). This study was particularly
important in putting two issues into context. 1) The isolation of viruses in CAP is much more frequent
than was previously thought, thanks to molecular techniques; and 2) Although molecular techniques are
better than microbiological cultures, these methods are not perfect in terms of operational values.
Diagnosis commonly involves antigen tests, culture, serology and molecular assays, all of which have their
own advantages and limitations (table 2), such as: specimen type, site and time of collection with respect
to illness onset, and the pretest probability (e.g. seasonal peaks), which may significantly affect test
performance [64–66]. Testing is generally recommended in hospitalised patients because specific
antimicrobial treatments (e.g. neuraminidase inhibitors for influenza, or macrolides, fluoroquinolones, or
doxycycline for atypical pathogens) are available and diagnosis may assist effective implementation of
isolation precautions [61, 64, 65, 67, 68].
Influenza (seasonal, pandemic, avian) is the most important cause of viral pneumonia, leading to high
morbidity and mortality; however, clinical diagnosis is unreliable [64, 65]. Rapid Influenza Diagnostic
Tests (RIDT, antigen immunoassays) are convenient, commercially available and highly specific (90–95%).
The major drawback is their low sensitivity (40–70%), which means that a negative result cannot rule out
influenza infection [65, 69–71]. The tests’ performance does improve if they are applied within 48–72 h of
illness onset, before significant viral-load drop occurs [65, 66]. Similar considerations apply to
immunofluorescence antigen assays, although they are generally more sensitive (50–85%), can be used in
upper and lower respiratory specimens (e.g. tracheal aspirates, bronchoalveolar lavage) and can detect a
range of respiratory viruses (e.g. respiratory syncytial virus (RSV), parainfluenza virus) if included in the
panel. Laboratory expertise is essential, as is the availability of quality specimens with abundant epithelial
cells for staining [64, 65]. Generally, serology and culture cannot assist patient care because of their
retrospective or slow results, but they are useful for surveillance and research purposes (e.g. for strain
identification and phenotypic resistance testing) [65, 72, 73].
Where available, PCR is now considered the test of choice, due to its high sensitivity and specificity,
greater time window for detection and rapid turnaround time [64, 65, 71]. It can detect all influenza A
subtypes with the universal primers (targeting the M-gene, as for influenza B), or individual subtypes
using specific primers (e.g. H1, H3, H5, H7) [74]. This information may have implications for treatment
(e.g. pre-pandemic H1N1 is oseltamivir-resistant) and may identify possible novel or avian strains (e.g.
H1N1pdm09 and H7N9 are initially “untypable” using existing primers) [69, 72, 74, 75].
Even with PCR, negative results may occur with nasopharyngeal samples in the case of influenza
pneumonia due to differential viral kinetic changes along the respiratory tract. Additional testing with a
lower respiratory sample (in which viral loads are generally higher) should therefore be considered [66, 69,
75, 76].
Notably, PCR does not provide information regarding infectiousness and dead virus RNA fragments may
be detected, albeit at a low level, even upon clinical resolution [74]. Semi-quantitative, real-time assays may
be useful for the monitoring of virologic response (cycle-threshold values have been used as alternative
estimates) [66, 73, 76]. Rapid, direct detection of genotypic resistance is also possible with PCR for known
mutations (e.g. H275Y in H1N1pdm09) [72–74].
As manifestations of influenza are indistinguishable from other respiratory pathogens, multiplex PCR
platforms that detect a range of common viruses (e.g. influenza, RSV, human metapneumovirus,
parainfluenza virus, rhinovirus) and atypical pathogens (e.g. M. pneumoniae, Chlamydophila pneumoniae)
are increasingly being used in the clinical setting [59, 63, 71, 77]. More recently, molecular-based
point-of-care tests (loop-mediated isothermal amplification (LAMP) of nucleic acids, real-time PCR) have
become available for detecting influenza and other viruses at the bedside, offering a degree of accuracy
comparable to conventional laboratory PCR assays [68, 71]. However, the impact of these molecular assays
on clinical outcomes and their cost-effectiveness remain unclear and they deserve further evaluation [78].
RSV causes major morbidity in children and older adults, with burdens, manifestations and severity
comparable to influenza. Specific antivirals (e.g. fusion inhibitors) are in the pipeline [79, 80]; however,
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TABLE 2 Laboratory diagnosis of S. pneumoniae, atypical pathogens and respiratory viruses in the clinical setting.
Pathogen Diagnostic method
Culture Antigen test Blood culture PCR
S. pneumoniae Positive in 60–80% of good quality
sputum samples
Between 17 and 35% of CAP patients
can expectorate sputum of
adequate quality [3, 43, 51]
Results in <30 min
ICT: sensitivity 60–85% and specificity 99%
UAD: sensitivity 98% and specificity 99% [51]
Definitive diagnosis
Positive in less than 10% of
pneumococcal CAP cases
Results in 1–2 days [43, 51]
Results within hours
High sensitivity/specificity
Allows diagnosis of early, low bacterial
load disease
Lower influence of previous antibiotic
treatment
Accessibility, technical demands and
cost are practical concerns, as is lack
of standardisation [3, 51, 62]
L. pneumophila Sensitivity 50–80% with high
specificity (“gold standard”)
Allows detection of different L.
pneumophila strains
Technically demanding-requires
optimal sampling and
post-sampling processing
conditions
False-negative results may occur in
late or treated infections
Results are too slow to guide patient
care [9]
Results in <30 min
Sensitivity 75-80%; specificity 99–100%
Unreliable for non-serogroup 1 infections
Positive results may indicate recent infection
“False-negatives” may occur in early infection
Concomitant culture of respiratory secretions in
selective media is recommended, especially
in immunocompromised patients [98, 99]
Results within hours
High sensitivity and specificity
Allows diagnosis of early, low bacterial
load, and non-serogroup 1 infections
Accessibility, technical demands and
cost are practical concerns
Lack of standardisation
Respiratory specimens may be
unavailable [48]
RIDT [82] DFA or IFA [74, 75, 82] Viral cell culture [75, 80, 85] RT-PCR [67, 71, 81, 83]
Influenza virus Immunoassay for antigens
Results in <30 min
Applicable to a range of upper
respiratory samples
Differentiates between influenza
A/B
Specificity 90–95%
Sensitivity 40–70%
Unable to distinguish between
virus subtypes
Direct or indirect immunofluorescence antibody
staining
Results within hours
Applicable to upper and lower respiratory
samples
Detects influenza A, B and other viruses
simultaneously if included in the panel
Specificity 90–95%
Sensitivity 50–85%
A quality specimen containing adequate
epithelial cells together with laboratory
expertise is essential
Unable to distinguish between virus subtypes
Conventional or shell-vial viral
cell culture
High specificity
Sensitivity 7–20%
Allows virus subtyping, strain
identification, titre assay/
quantification and resistance
testing
Provides information on
infectiousness
Requires optimal sampling and
post-sampling processing
conditions
Results too slow to guide patient
care (conventional culture:
>3–10 days; shell-vial culture:
>2–3 days)
Reverse-transcription polymerase chain
reaction
Results within hours
High sensitivity and specificity (“gold
standard”)
Applicable to a wider range of specimen
types
Able to distinguish between virus
subtypes and detect genotypic
resistance
Multiplex PCR methods may allow
simultaneous detection of other
respiratory pathogens
Accessibility, technical demands and
cost are practical concerns
Unable to distinguish non-viable from
viable viruses
“False-negatives” may result from
site-differential viral kinetic changes
in pneumonia cases
Continued
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TABLE 2 Continued
Pathogen Diagnostic method
Serology [95, 96] Molecular assay [96]
M. pneumoniae Includes ELISA, CFT and particle agglutination
A four-fold rise in titre confirms the diagnosis of acute infection
A single, elevated IgM/IgA titre may indicate recent infection
Specificity 70–90%
Sensitivity 20–60%
Paired acute and convalescent serum (2–4 weeks apart) are required.
Results are thus retrospective
“False-positives” may occur with IgM tests and with previous infection
Results within hours
High sensitivity, moderate-to-high specificity
Accessibility, technical demands and cost are practical concerns
Lack of standardisation
Specimen of choice is uncertain
Cannot distinguish acute infection from asymptomatic carriage,
especially in children
CAP: community-acquired pneumonia; ICT: immunochromatographic assay; UAD: serotype-specific urinary antigen detection assay; RIDT: rapid influenza diagnostic test; DFA: direct
immunofluorescence antibody staining; IFA: indirect immunofluorescence antibody staining; ELISA: enzyme-linked immunosorbent assay; CFT: complement fixation test.
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diagnosis can be difficult because of the low sensitivity of antigen assays (20–60%, higher in children), and
culture is slow and technically challenging [78, 79]. The more sensitive PCR assays (singleplex, multiplex)
are becoming the tests of choice, especially in adults who generally present with lower viral loads [71, 78,
81]. Similarly, in RSV pneumonia, lower respiratory samples including sputum should also be considered
if available; use of a quality sputum sample and methods to overcome the difficulties in its processing have
been suggested [63, 76, 78]. Testing for other viruses (commonly with multiplex assays) is gaining
importance because of the increasing recognition of their roles in causing lower respiratory infections,
hospitalisations and ICU admissions; clinical trials of broad-spectrum or virus-specific agents are
underway (e.g. nitazoxanide-NCT01227421, favipiravir-NCT01728753 and DAS181-NCT01644877) [59,
63, 68, 74, 79]. Lessons from epidemics caused by emerging pathogens suggest that careful laboratory
evaluation of undiagnosed pneumonia with molecular (e.g. H1N1pdm09, H7N9) and culture (e.g. severe
acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus) methods, together
with application of advanced techniques such as next-generation sequencing, are important for their
prompt detection [69, 79, 82].
Traditionally, atypical bacterial pathogens are not routinely diagnosed due to difficulties in performing
cultures and the lack of reliable tests [60, 61]. Single-titre IgM assays provide quicker results but are
limited by their moderate sensitivity (e.g. early disease, attenuated IgM response in adults) and specificity
(e.g. past infection, other infectious/non-infectious diseases) [83, 84].
Recent studies indicate high sensitivity for rapid molecular tests (e.g. LAMP, singleplex PCR, multiplex
PCR) which can be applied to a range of respiratory specimens including sputum and bronchoalveolar
lavage [71, 84]. Nevertheless, the methods have not been standardised (e.g. primer targets) and the optimal
specimen types remain uncertain. Improvements in diagnosis are urgently needed to guide specific therapy
because of the emergence of macrolide resistance worldwide (Asia 30–100%, USA/Europe 10–30%) and
the challenge this poses for empirical regimens against CAP (typically a β-lactam plus a macrolide) [83].
Similar issues exist for the serological and molecular diagnosis of acute C. pneumoniae infection, including
prolonged asymptomatic carriage and lack of standardisation [85]. In contrast, diagnostic methods for L.
pneumophila infection are well established and are described in current pneumonia management
guidelines [85, 86]. Briefly, urine antigen tests have high sensitivity (75–80%) and specificity (99–100%),
but only reliably diagnose the commonest serogroup (serogroup 1). More recent data suggest that PCR of
lower respiratory specimens, including sputum, allows the diagnosis of early, low bacterial load and
non-serogroup 1 infections. However, the presence of a dry cough may limit its use. Combining PCR with
urine tests may maximise the diagnostic yield [59, 85, 87].
Diagnosis of pneumonia caused by potentially multidrug-resistant bacteria
The most frequent multidrug-resistant bacteria involved in pneumonia are MRSA, P. aeruginosa,
Acinetobacter baumannii and various Enterobacteriaceae [23, 25, 88–90]. The reference diagnostic
techniques used to identify the bacteria causing respiratory tract infections remain the Gram stain and
semi-quantitative conventional culture from direct respiratory samples, followed by bacterial identification
using MALDI-TOF (matrix-assisted laser desorption/ionisation time-of-flight) mass spectrometry [91–93]
and susceptibility testing of the potential pathogen [94]. In addition to the difficulty of differentiating
between colonisation and infection, this process requires a minimum of 2 days and has low sensitivity,
especially if the sample is taken after the start of antibiotic treatment [40]. As a consequence, many
patients receive inappropriate antibiotic treatment, which may increase morbidity and mortality [16, 95–
97]. This statement is also valid for conventional bacteria.
Current guideline recommendations for multidrug-resistant pathogens (MRSA, P. aeruginosa and
drug-resistant S. pneumoniae) include the use of respiratory fluoroquinolone or ß-lactam plus macrolide in
outpatients. For inpatients, ICU patients and suspected P. aeruginosa infections, the use of an
anti-pneumococcal, anti-pseudomonal ß-lactam plus either ciprofloxacin or levofloxacin; ß-lactam plus an
aminoglycoside; or ß-lactam plus an aminoglycoside and an anti-pneumococcal fluoroquinolone are
recommended. For community-acquired MRSA, the recommendation is to add vancomycin or linezolid.
There are several scoring systems to identify CAP patients with risk factors for acquiring
multidrug-resistant pathogens. Of these, two systems, the clinical scores by SHORR et al. [14] and ALIBERTI
et al. [13] categorise risk factors into groups: In the system devised by SHORR et al. [14], points are
allocated for recent hospitalisation (4 points), nursing home residence (3 points), haemodialysis (2 points)
and ICU admission (1 point). Patients with less than 3 points have a 20% prevalence of
multidrug-resistant pathogens whereas patients with more than 5 points have a prevalence of 75%. The
system developed by ALIBERTI et al. [13] assigns points to hospitalised patients with CAP involving chronic
renal failure (5 points), prior hospitalisation (4 points), residence in a nursing home (3 points) and other
risk factors (0.5 points each). Patients with at least 3 points have a prevalence of multidrug-resistant
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pathogens of 38% whereas patients with a score of ⩽0.5 points have a prevalence of 8%. Molecular
diagnosis, such as with dedicated PCR assays, has partly overcome the difficulties mentioned [98]. In
recent years, molecular techniques based on multiplex PCR have also been developed in order to
simultaneously identify and quantify multiple respiratory pathogens from different types of samples in a
single procedure (table 3) [99–103].
Another challenge for the rapid diagnosis of respiratory infections is early detection of the antibiotic
resistance profile of the various bacteria [104]. The biggest obstacle in the use of molecular techniques for
detecting resistance is the discrepancy between genotype and phenotype [105]. New resistance mechanisms
are continually being discovered and, as a result, the potential presence of unknown mechanisms may lead
to false-negative results using molecular techniques [106]. An additional problem is the detection of
genotypic markers which phenotypically do not show clinically significant resistance [105].
Despite the drawbacks of molecular techniques, early information on the resistance profile is more likely
to improve empirical treatment than no information at all [106]. An assay based on multiplex PCR is
currently under development, which can detect some bacterial resistance markers involved in causing
respiratory infection, including the genes related to β-lactam resistance (mecA, blaTEM, blaSHV, blaCTX-M,
blaDHA, blaEBC, blaOXA-51 and blaKPC), macrolides/lincosamides (ermA, ermB, ermC, msrA and mefA),
fluoroquinolones (detection of changes in the amino acid codons gyrA83and gyrA87 of GyrA and in
ParC) and markers of class 1 integrons (int1 and sul1) [107].
Recently, a new group of molecular techniques has emerged based on LAMP[108]. Unlike conventional
PCRs, in which a series of temperature change cycles are required for the amplification of nucleic acids,
these techniques allow amplification at a constant temperature. ZHANG et al. [109] applied this technique to
the rapid diagnosis of major pathogenic bacteria (S. pneumoniae, S. aureus, Escherichia coli, Klebsiella
pneumoniae, P. aeruginosa, A. baumannii, Stenotrophomonas maltophilia and H. influenzae) in 120 sputum
samples from patients with suspected chronic obstructive pulmonary disease exacerbations. LAMP obtained
more positive results than conventional cultures and a higher correlation with clinical symptoms as well.
In a recent study by KONCAN et al. [110], a new methodology called “respiFISH” was developed that
combined classical fluorescence in situ hybridisation (FISH) technology with fluorescence-labelled DNA
TABLE 3 Laboratory diagnosis of pneumonia caused by potentially multidrug-resistant
bacteria.
Diagnostic method Advantages Disadvantages
Culture [3, 42, 60] Easy to perform and cheap
Isolation and identification of
bacteria whose detection by other
methods has not been
standardised (i.e., S. maltophilia)
The susceptibility of the isolated
pathogens can be assessed
Turnaround time (1–2 days)
Low sensitivity, especially if sample is
taken after starting antibiotic
treatment
Sometimes difficult to differentiate
infection from colonisation
Molecular assay
(Singleplex) [3, 48,
52, 60, 66, 69]
High turnaround time
High sensitivity and specificity
Allows diagnosis of early, low
bacterial load disease
Lower influence of antibiotic
pretreatment compared to
conventional culture
Allows detection of resistance
markers (i.e., mec gene for MRSA)
Cost is a concern
Only detects one pathogen
Does not determine susceptibility to all
antibiotics-a conventional antibiogram
remains the “gold standard”
Molecular assay
(Multiplex) [9, 56,
93, 113, 117]
High turnaround time (1–6 h)
High sensitivity and specificity
Allows diagnosis of early, low
bacterial load disease
Lower influence of antibiotic
pretreatment compared to a
conventional culture
Detection of some resistance
markers
Cost is the main current concern
Not all pathogens causing respiratory
tract infections are included in the
multiplex panel
Does not determine susceptibility to all
antibiotics-a conventional antibiogram
remains the “gold standard”
MRSA: methicillin-resistant S. aureus
10 DOI: 10.1183/13993003.01144-2016
RESPIRATORY INFECTIONS | A. TORRES ET AL.
molecular beacons as probes. This was used to analyse 165 respiratory samples, including 85 sputa, 79
bronchial secretions (75 bronchial aspirates and four bronchial lavages) and one tracheal aspirate. The
sensitivity of this methodology was 94.39% and its specificity was 87.93%. The hands-on time of the assay
was approximately 30 min.
VINCENT et al. [111] described a PCR followed by electrospray ionisation mass spectrometry, which could detect
more than 800 infection-relevant bloodstream pathogens in a single assay in patients with sepsis and or
healthcare-associated pneumonia, ventilator-associated pneumonia, or severe CAP. This study showed that
applying this diagnostic method resulted in a three times higher identification of organisms in blood than using
standard cultures and, more importantly, changed the antibiotic treatment in 57% of the included patients.
The lung microbiome
In recent years, new culture-independent methods have shown that the lungs, previously thought to be
sterile, have a diversity of microbial communities [112, 113]. These communities exist in the absence of
infection and they are modified in the event of an acute or exacerbated infection (figure 2) [113] Q1
¶
. The
pathogenic micro-organisms found in pneumonia (e.g. S. pneumoniae) are only some of those that have
access to the lower respiratory tract but can also be identified in the lung microbiota of patients without
acute pneumonia [114].
CHEN et al. [114] studied the microbiome in sputum samples from 45 patients with CAP. They found
similarities with healthy controls at phyla level, and at genera level they found stability for Streptococcus
spp. and Neisseria spp. but changes in Moraxella spp. and Rothia spp. They concluded that Rothia spp.
may be an endogenous pneumonia-causing pathogen. In elderly patients with pneumonia, WOUTER et al.
[115] observed three microbiota profiles strongly associated with pneumonia: lactobacilli, S. pneumoniae
and Rothia spp. They suggested that pneumonia in elderly patients with dysbiosis of the upper respiratory
tract microbiome had bacterial overgrowth of a single species and distinct anaerobic bacteria.
ABELES et al. [116] studied the effect of the two most commonly prescribed antibiotics in the USA
(amoxicillin and azithromycin) to discern whether short-term antibiotic use had any prolonged effect on
human microbiota. As antibiotics are often absorbed across the gastrointestinal tract and distributed to the
tissues via the bloodstream, they expected that each would affect the microflora of each body surface tested
(gut, skin and mouth). The authors found that as few as 3 days of treatment with the most commonly
prescribed antibiotics could result in sustained reduction in microbiota diversity, which may have
implications for the maintenance of human health and resilience to disease.
Although there is still a long way to go, we are sure that, in the coming years, better knowledge and
understanding of the lung (and gut) microbiome will change our view of the physiopathology, treatment
and prevention of pneumonia.
Molecular techniques in clinical practice
Rapid diagnostic tests identify a specific pathogen or help to distinguish between bacterial and viral
infection; provide information about antibiotic susceptibility; monitor response to antibiotic therapy; assess
prognosis; aid antimicrobial stewardship; and give information for disease surveillance.
These technologies can be applied to different patient populations ranging from outpatients (allowing safe
discharge) to patients that need ICU treatment. The quick results (1–2 h) may be useful in the decision
management of critical patients especially in the prompt initiation of appropriate antimicrobial therapy, a
factor associated with mortality. Also, rapid identification of antibiotic resistant pathogens is central to
timely isolation of patients [19]. However, there are still two major challenges to face. 1) The differentiation
between colonisation and infection is still an issue for clinicians, except probably in the case of S.
pneumoniae and we do not have enough evidence for all these techniques to draw conclusions regarding
this. 2) The relative costs and outcomes of diagnostic testing must be considered when the decision to
implement these rapid tests is taken by healthcare systems-further studies on cost-effectiveness are needed.
Conclusions and implementation
The combination of new and old techniques will improve our ability to detect the microbes that cause
pneumonia more precisely and rapidly. This strategy will ensure that patients receive the most appropriate
antimicrobial therapy and may reduce the use of broad-spectrum antibiotics, thereby reducing antibiotic
resistance (figure 1). Since the majority of studies described in this review show the potential advantages
of molecular techniques, such as improved sensitivity and improved speed in establishing a microbiological
diagnosis, more studies are needed to systematically and rigorously evaluate their performance
characteristics, determine how these new technologies will improve diagnostic testing for respiratory
pathogens and effect patient management during their future implementation in daily practice. To
DOI: 10.1183/13993003.01144-2016 11
RESPIRATORY INFECTIONS | A. TORRES ET AL.
distinguish between colonisation and infection, the use of a quantitative cut-off for the number of
colony-forming units (⩾10-5 CFU·mL-1, as described in previous studies) is recommended [49, 53, 54,
117]. For implementation of these techniques it is necessary to discuss with the microbiology department
and the treating specialist which molecular tests need to be used and which pathogens should be targeted.
Although recent publications regarding the apparent utility of multiplex molecular procedures in the
detection of CAP pathogens are encouraging, significant concerns remain [49, 53, 54]. A protocol
addressing these issues should be developed and evaluated. A key question in this evaluation is whether
our current clinical practice needs to change. Will there be a change in prescribing antibiotics and, if so,
would it improve antibiotic stewardship? Furthermore, a close evaluation of costs needs to be
implemented. Finally, the concepts regarding the lung microbiome are very promising and are currently
the focus of many studies. We believe that these concepts will change our understanding of pulmonary
infection, how to prevent it and how to improve its treatment.
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